Use of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections

Publisher Website
Google Scholar
Abstract
The therapeutic efficacy and safety of ciprofloxacin was studied in 30 patients withPseudomonas aeruginosa infections. In 20 patients ciprofloxacin was given alone and in 10 patients (including 8 compromized hosts) in combination with an aminoglycoside (9) or azlocillin (1). Ciprofloxacin was given in doses of 500 mg orally or 200–300 mg i. v. every 12 h. In patients receiving only ciprofloxacin clinical cure with eradication of bacteria was obtained in 15 patients (75%) with infections of bone and joint (6), skin and soft tissue (4), lung (2), middle ear (2) and CSF (1). Two patients with lymphoma andPseudomonas aeruginosa pneumonia died. In patients receiving combination therapy a definite therapeutic success was achieved in four (40%). Three patients withPseudomonas aeruginosa septicemia died. In seven patients nine bacterial strains with decreasing susceptibility of ciprofloxacin (increase in MIC from ⩽0.5μg/ml to 2–16 μg/ml) were selected (6Pseudomonas aeruginosa, 1Enterobacter cloacae, 1Serratia marcescens, 1Staphylococcus aureus). Ciprofloxacin was well tolerated. This new quinolone seems to be suitable for single drug treatment ofPseudomonas aeruginosa infections in patients with normal host defense mechanisms, while its therapeutic potential in compromized hosts requires further evaluation.

This publication has 13 references indexed in Scilit: